ArticleNature communications2024

Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer.

Ashenafi Bulle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.